A Study of IBI363 in Subjects with Advanced Solid Malignancies

Inclusion Criteria:

1. Subjects have the ability to understand and give written informed consent forparticipation in this trial, including all evaluations and procedures as specifiedby this protocol;

2. Male or female subjects ≥ 18 years old;

3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;

4. Anticipated life expectancy of ≥ 3 months;

Exclusion Criteria:

1. Inadequate bone marrow and organ function;

2. Received previous anti-tumor therapy: Any chemotherapy or targeted small moleculetherapy (standard or investigational) within 2 weeks or 5 plasma half-lives.Received Nitrosoureas and mitomycin C within 6 weeks prior to first dose of studydrug and during study; Any anti-cancer monoclonal antibody (mAb) within 4 weeksprior to first dose

3. Received live vaccines within 28 days prior to first administration of the studydrug or plan on receiving any live vaccine during the study;

4. Has adverse reactions resulting from previous antitumor therapies, which have notresolved to Grade 0 or 1 toxicity according to NCI-CTCAE v5.0 (except for alopecia,fatigue, pigmentation and other conditions with no safety risk according toinvestigator' discretion) or baseline prior to the first dose of the study drug;

5. Undergone major surgery (Craniotomy, thoracotomy or laparotomy, and other surgeryaccording to investigator' discretion, excluding needle biopsy) within 4 weeks priorto the first dose of the study drug, or who are expected to undergo major surgeryduring the study period, or who have severe unhealed wounds, trauma, ulcers, etc.